Please Scroll Down to See Forums Below
SOMATORM GH.... Real or not?
- Thread starter BionicBC
- Start date
PitBullFootBall
New member
Kingwinny said:is the somatorm 191 amino like serostim or 192 like Kexing?
191 amino acid sequence
PitBullFootBall
New member
Honkey Tonk said:
I haven't heard any horror stories either - were they pulled down?
A
Alright123
Guest
PitBullFootBall said:
No, there simply havent been any. There would be no reason for them to be pulled down either, they are not a sponser here.
Somatorm is Ansomone by Ankebio relabeled by Pharmacia El Ramoz. The products inserts for each were verbatim a few weeks ago. The Somatorm site even left the reference to Ansomone until recently when I posted this on another site. Thereafter, the word "Ansomone" was removed but everything else is verbatim. Somatorm also has a red cap like Ansomone. Which leads me to this conclusion. See for yourself.
http://www.pharmacia-elramoz.com/image/p1.jpg
From Ansomone Site:
BRIEF INTRODUCTION
is a kind of sterile, lyophilized formulation of Recombinant Human Growth Hormone (HGH) with 191 amino acids, derived from engineering E.coli, and it is identical to the natural growth hormone in amino acid sequence and three-dimension structure. is indicated for growth failure due to endogenous growth hormone deficiency (GHD) and Turner disease or Kidney failure. can be used to heal up the surgery wound or burned wound and it has good effect to preservation for human aging. Our manufacturing plants of are certified for GMP Standard by SFDA.
SPECIFICATION AND INSTRUCTION
PRODUCT NAME
Generic name: Recombinant Human Growth Hormone for Injection
Trade name: Ansomone®
Chinese Phoneticize: Zhusheyong Chongzu Ren Shengzhangjisu
Composition in effect: Recombinant Human Growth Hormone
DESCRIPTION
White loose lyophilized powder.
PHARMACOLOGY AND TOXICOLOGY
Ansomone® exerts the same actions of endogenous human growth hormone. It can stimulate proliferation and differentiation of epiphysis chondrocyte, stimulate growth of cartilage matrix cells, stimulate proliferation and differentiation of osteoblast; thus accelerate the liner growth rate and improve epiphysis width. Ansomone® can promote protein synthesis in whole body; reverse the negative nitrogen equilibrium caused by wound and surgery; correct the hypoproteinemia due to severe infection or hepatocirrhosis; stimulate synthesis of immune globin and proliferation of lymphadenoid, macrophage and lymphocyte, thus enhance the ability of infection resistance; stimulate proliferation of collagenocyte, fibroblast and macrophage in sites of burn and surgery, thus accelerate wound healing; promote synthesis of cardiocytes, thus improve cardiac contractility and reduce cardiac oxygen consumption; regulate lipometabolism, thus depress serum cholesterol and low density lipoprotein's level; complement insufficiency or deficiency of growth hormone, regulate adult's lipometabolism, osteometabolism, heart and kidney function.
PHARMACOKINETICS
It is reported that the equal pharmacological effect could be achieved via subcutaneous (sc) or intramuscular (IM) administration. Even though sc may lead a higher concentration of GH in plasma, IM could also yield the same IGF-I level. The absorption of GH is the relatively slow, Cmax often occurs at 3-5 hours after injection. Clearance of GH is via liver and kidney, the half-life of clearance is about 2-3hours. Uncatabolized GH excreted in urea is almost immeasurable. All of the GH in circulation system exists as a complex form with GH binding proteins that make the half-life of GH prolonged.
INDICATIONS
Ansomone® is indicated for the growth failure of children due to endogenous growth hormone deficiency (GHD), chronic renal insufficiency (CRI) and Turner's syndrome. Ansomone® is indicated for severe burn.
More information
USAGE
When reconstitution, 1ml water for injection should be injected along the bottle wall, then swirl the vial with a gentle rotary motion until the contents are completely dissolved, do not shake violently.
The recommended dosage of Ansomone® for the treatment of children growth failure is 0.1~0.15IU/kg daily subcutaneous administration for 3 months to 3 years. Therapy regimen could be modified according to experienced doctor's suggestion.
The recommended dosage of Ansomone® for the treatment of severe burn is 0.2~0.4IU/kg daily subcutaneous administration for 2 weeks.
ADVERSE REACTIONS
Growth hormone may cause transient hyperglycemia; it can be recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in clinical trial. Common adverse reactions include slight pain, tingle, turgescence around the injection site and peripheral edema, arthralgias. All of those adverse reactions often occurred at the beginning of treatment, and were temporal and tolerable.
Long-term and high dosage administration of hGH may develop the antibodies in a few patients. However, the antibodies concentration could be rarely up to as high as 2mg/L that might affect the therapeutic efficiency.
CONTRAINDICATIONS
1. Ansomone® should not be used in children whose epiphysis had been closed.
2. Ansomone® should not be used in cancer patients.
3. Ansomone® should not be used in patients in acute shock stage with severe infection.
WARNINGS AND PRECAUTIONS
1. hGH therapy should be conducted on exactly diagnosed GHD patients under advice of experienced doctor.
2. For diabetes patients, dosage of anti-glucourea drugs should be adjusted during HGH therapy.
3. For patients whose GHD were caused by encephaloma or encephalic wound, the progress and the relapse possibility of potential diseases should be closely monitored.
4. For ACTH deficiency patients, dosage of ATCH should be adjusted because the growth improvement effect of HGH could be inhibited by simultaneous using of ACTH.
5. Thyroid gland function should be tested regularly because clinical hypothyroidism may occur to some patients during HGH therapy. For those hypothyroid, thyroid supplementation is necessary for ensuring the therapeutic effects of HGH.
6. Careful consideration should be taken if claudicating occurred during HGH therapy because the patients who suffered from endocrine system diseases (including GHD) have such a tendency that their epiphysis plates of femur are relatively easy to separate.
7. Growth hormone may lead to over insulin state, attention should be paid to if lower glucose intolerance appeared.
8. Do not take over-dose of HGH, one time over-dose HGH administration can lead to low blood sugar and succeeded with high blood sugar. Long-term over -dose HGH administration can lead to acromegaly.
9. Injection site should often variation in case lipoatrophy.
PREGNANT AND BABY-NURSING WOMEN USAGE
It is not recommended for pregnant and nursing women to accept HGH therapy.
PEDIATRIC USAGE
Response to HGH of children is similar to that of adults in pharmacology, toxicology and pharmacokinetics, HGH is safe for pediatric use.
OLD PATIENTS USAGE
Response to HGH of old patients is similar to that of adults in pharmacology, toxicology and pharmacokinetics, HGH is safe for geriatric use.
INTERACTION WITH OTHER DRUGS
Responses to HGH therapy might be inhibited by glucocorticoid, so that hydrocortisone dosage would be lower than 10~15mg/m2 of body surface during HGH therapy.
Simultaneous using of non-androgenic steroid during HGH therapy can accelerate growth rate.
OVERDOSAGE
There is yet no report about over dosage of HGH; however, over dosage may cause some side effects, such as hypoglycemia at the beginning then succeeded with hyperglycemia. Long-term over dosage using of HGH can lead to acromegaly.
VIAL SIZE
2, 4 IU/vial
STORAGE
Keep at 2~8? away from light. The reconstituted solution mixed with Sterile Water for Injection can be stored at 2~8? for 48 hours, do not be frozen.
EXPIRY
2 years
LICENCES
GYZZS19990021(4IU/vial)
GYZZS19990022(2IU/vial)
From Somatorm site:
SOMATORM INJECTION PRODUCT INSERT
PHARMACIA EL RAMOZ GENE AND CELL PRODUCTS
SOMATORM INJECTION- Recombinant Human Growth Hormone for InjectionK
(Somatropin/rHGH, rDNA Origin)
BRIEF INTRODUCTION
is a kind of sterile, lyophilized formulation of Recombinant Human Growth Hormone (rHGH) derived from engineering E.coli, and it is identical to the natural growth hormone in amino acid sequence and three-dimension structure. is indicated for growth failure due to endogenous growth hormone deficiency (GHD) and Turner disease or Kidney failure. can be used to heal up the surgery wound or burned wound and it has good effect to preservation for human aging. Our manufacturing plants of are certified for GMP Standard by SDA.
SPECIFICATION AND INSTRUCTION
PRODUCT NAME: SOMATORM injection
Composition in effect: Recombinant Human Growth Hormone
DESCRIPTION
White loose lyophilized powder.
PHARMACOLOGY AND TOXICOLOGY
rHGH exerts the same actions of endogenous human growth hormone. It can stimulate proliferation and differentiation of epiphysis chondrocyte, stimulate growth of cartilage matrix cells, stimulate proliferation and differentiation of osteoblast; thus accelerate the liner growth rate and improve epiphysis width. Ansomone? can promote protein synthesis in whole body; reverse the negative nitrogen equilibrium caused by wound and surgery; correct the hypoproteinemia due to severe infection or hepatocirrhosis; stimulate synthesis of immune globin and proliferation of lymphadenoid, macrophage and lymphocyte, thus enhance the ability of infection resistance; stimulate proliferation of collagenocyte, fibroblast and macrophage in sites of burn and surgery, thus accelerate wound healing; promote synthesis of cardiocytes, thus improve cardiac contractility and reduce cardiac oxygen consumption; regulate lipometabolism, thus depress serum cholesterol and low density lipoprotein's level; complement insufficiency or deficiency of growth hormone, regulate adult's lipometabolism, osteometabolism, heart and kidney function.
PHARMACOKINETICS
It is reported that the equal pharmacological effect could be achieved via subcutaneous (sc) or intramuscular (IM) administration. Even though sc may lead a higher concentration of GH in plasma, IM could also yield the same IGF-I level. The absorption of GH is the relatively slow, Cmax often occurs at 3-5 hours after injection. Clearance of GH is via liver and kidney, the half-life of clearance is about 2-3hours. Uncatabolized GH excreted in urea is almost immeasurable. All of the GH in circulation system exists as a complex form with GH binding proteins that make the half-life of GH prolonged.
INDICATIONS
rHGH is indicated for the growth failure of children due to endogenous growth hormone deficiency (GHD), chronic renal insufficiency (CRI) and Turner's syndrome. Ansomone? is indicated for severe burn.
USAGE
When reconstitution, water for injection should be injected along the bottle wall, then swirl the vial with a gentle rotary motion until the contents are completely dissolved, do not shake violently.
The recommended dosage of rHGH for the treatment of children growth failure is 0.1~0.15IU/kg daily subcutaneous administration for 3 months to 3 years. Therapy regimen could be modified according to experienced doctor's suggestion.
The recommended dosage of rHGH for the treatment of severe burn is 0.2~0.4IU/kg daily subcutaneous administration for 2 weeks.
ADVERSE REACTIONS
Growth hormone may cause transient hyperglycemia; it can be recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in clinical trial. Common adverse reactions include slight pain, tingle, turgescence around the injection site and peripheral edema, arthralgias. All of those adverse reactions often occurred at the beginning of treatment, and were temporal and tolerable.
As with most proteins some users may report minor iritation at the injection sites via subqutaneous injection methods.
CONTRAINDICATIONS
rHGH should not be used in children whose epiphysis had been closed.
rHGH should not be used in cancer patients.
rHGH should not be used in patients in acute shock stage with severe infection.
WARNINGS AND PRECAUTIONS
rhGH therapy should be conducted on exactly diagnosed GHD patients under advice of experienced doctor.
For diabetes patients, dosage of anti-glucourea drugs should be adjusted during rhGH therapy.
For patients whose GHD were caused by encephaloma or encephalic wound, the progress and the relapse possibility of potential diseases should be closely monitored.
For ACTH deficiency patients, dosage of ATCH should be adjusted because the growth improvement effect of rhGH could be inhibited by simultaneous using of ACTH.
Thyroid gland function should be tested regularly because clinical hypothyroidism may occur to some patients during rhGH therapy. For those hypothyroid, thyroid supplementation is necessary for ensuring the therapeutic effects of rhGH.
Careful consideration should be taken if claudicating occurred during rhGH therapy because the patients who suffered from endocrine system diseases (including GHD) have such a tendency that their epiphysis plates of femur are relatively easy to separate.
Growth hormone may lead to over insulin state, attention should be paid to if lower glucose intolerance appeared.
Do not take over-dose of rhGH, one time over-dose rhGH administration can lead to low blood sugar and succeeded with high blood sugar. Long-term over -dose rhGH administration can lead to acromegaly.
Injection site should often variation in case lipoatrophy.
PREGNANT AND BABY-NURSING WOMEN USAGE
It is not recommended for pregnant and nursing women to accept rhGH therapy.
PEDIATRIC USAGE
Response to rhGH of children is similar to that of adults in pharmacology, toxicology and pharmacokinetics, rhGH is safe for pediatric use.
OLD PATIENTS USAGE
Response to rhGH of old patients is similar to that of adults in pharmacology, toxicology and pharmacokinetics, rhGH is safe for geriatric use.
INTERACTION WITH OTHER DRUGS
Responses to rhGH therapy might be inhibited by glucocorticoid, so that hydrocortisone dosage would be lower than 10~15mg/m2 of body surface during rhGH therapy.
Simultaneous using of non-androgenic steroid during rhGH therapy can accelerate growth rate.
OVERDOSAGE
There is yet no report about over dosage of rhGH; however, over dosage may cause some side effects, such as hypoglycemia at the beginning then succeeded with hyperglycemia. Long-term over dosage using of rhGH can lead to acromegaly.
VIAL DOSE
10mg, 20mg, 40mg.
Kit packs-multi vials.
1mg= 3IU
UNIQUE FORMULATION
SOMATORM conatins a unique formulation of preservatives which preserves and stabilizes the rhGH both in its dry & diluted states unlike other brands.
STORAGE
Keep away from light.
SOMATORM is stable at room temp before being diluted and is not compulsory to refrigerated(recommended). Unlike other brands which dont have this stability.
Once reconstituted the solution must be refrigerated very cold at all times(do not freeze).
Once diluted with the supplied solution SOMATORM is stable up to 2>4 weeks maximum(whilst refrigerated very cold) due to its unique formulation. Unlike other brands which are only stable for a few days.
EXPIRY
2 years
http://www.pharmacia-elramoz.com/image/p1.jpg
From Ansomone Site:
BRIEF INTRODUCTION
is a kind of sterile, lyophilized formulation of Recombinant Human Growth Hormone (HGH) with 191 amino acids, derived from engineering E.coli, and it is identical to the natural growth hormone in amino acid sequence and three-dimension structure. is indicated for growth failure due to endogenous growth hormone deficiency (GHD) and Turner disease or Kidney failure. can be used to heal up the surgery wound or burned wound and it has good effect to preservation for human aging. Our manufacturing plants of are certified for GMP Standard by SFDA.
SPECIFICATION AND INSTRUCTION
PRODUCT NAME
Generic name: Recombinant Human Growth Hormone for Injection
Trade name: Ansomone®
Chinese Phoneticize: Zhusheyong Chongzu Ren Shengzhangjisu
Composition in effect: Recombinant Human Growth Hormone
DESCRIPTION
White loose lyophilized powder.
PHARMACOLOGY AND TOXICOLOGY
Ansomone® exerts the same actions of endogenous human growth hormone. It can stimulate proliferation and differentiation of epiphysis chondrocyte, stimulate growth of cartilage matrix cells, stimulate proliferation and differentiation of osteoblast; thus accelerate the liner growth rate and improve epiphysis width. Ansomone® can promote protein synthesis in whole body; reverse the negative nitrogen equilibrium caused by wound and surgery; correct the hypoproteinemia due to severe infection or hepatocirrhosis; stimulate synthesis of immune globin and proliferation of lymphadenoid, macrophage and lymphocyte, thus enhance the ability of infection resistance; stimulate proliferation of collagenocyte, fibroblast and macrophage in sites of burn and surgery, thus accelerate wound healing; promote synthesis of cardiocytes, thus improve cardiac contractility and reduce cardiac oxygen consumption; regulate lipometabolism, thus depress serum cholesterol and low density lipoprotein's level; complement insufficiency or deficiency of growth hormone, regulate adult's lipometabolism, osteometabolism, heart and kidney function.
PHARMACOKINETICS
It is reported that the equal pharmacological effect could be achieved via subcutaneous (sc) or intramuscular (IM) administration. Even though sc may lead a higher concentration of GH in plasma, IM could also yield the same IGF-I level. The absorption of GH is the relatively slow, Cmax often occurs at 3-5 hours after injection. Clearance of GH is via liver and kidney, the half-life of clearance is about 2-3hours. Uncatabolized GH excreted in urea is almost immeasurable. All of the GH in circulation system exists as a complex form with GH binding proteins that make the half-life of GH prolonged.
INDICATIONS
Ansomone® is indicated for the growth failure of children due to endogenous growth hormone deficiency (GHD), chronic renal insufficiency (CRI) and Turner's syndrome. Ansomone® is indicated for severe burn.
More information
USAGE
When reconstitution, 1ml water for injection should be injected along the bottle wall, then swirl the vial with a gentle rotary motion until the contents are completely dissolved, do not shake violently.
The recommended dosage of Ansomone® for the treatment of children growth failure is 0.1~0.15IU/kg daily subcutaneous administration for 3 months to 3 years. Therapy regimen could be modified according to experienced doctor's suggestion.
The recommended dosage of Ansomone® for the treatment of severe burn is 0.2~0.4IU/kg daily subcutaneous administration for 2 weeks.
ADVERSE REACTIONS
Growth hormone may cause transient hyperglycemia; it can be recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in clinical trial. Common adverse reactions include slight pain, tingle, turgescence around the injection site and peripheral edema, arthralgias. All of those adverse reactions often occurred at the beginning of treatment, and were temporal and tolerable.
Long-term and high dosage administration of hGH may develop the antibodies in a few patients. However, the antibodies concentration could be rarely up to as high as 2mg/L that might affect the therapeutic efficiency.
CONTRAINDICATIONS
1. Ansomone® should not be used in children whose epiphysis had been closed.
2. Ansomone® should not be used in cancer patients.
3. Ansomone® should not be used in patients in acute shock stage with severe infection.
WARNINGS AND PRECAUTIONS
1. hGH therapy should be conducted on exactly diagnosed GHD patients under advice of experienced doctor.
2. For diabetes patients, dosage of anti-glucourea drugs should be adjusted during HGH therapy.
3. For patients whose GHD were caused by encephaloma or encephalic wound, the progress and the relapse possibility of potential diseases should be closely monitored.
4. For ACTH deficiency patients, dosage of ATCH should be adjusted because the growth improvement effect of HGH could be inhibited by simultaneous using of ACTH.
5. Thyroid gland function should be tested regularly because clinical hypothyroidism may occur to some patients during HGH therapy. For those hypothyroid, thyroid supplementation is necessary for ensuring the therapeutic effects of HGH.
6. Careful consideration should be taken if claudicating occurred during HGH therapy because the patients who suffered from endocrine system diseases (including GHD) have such a tendency that their epiphysis plates of femur are relatively easy to separate.
7. Growth hormone may lead to over insulin state, attention should be paid to if lower glucose intolerance appeared.
8. Do not take over-dose of HGH, one time over-dose HGH administration can lead to low blood sugar and succeeded with high blood sugar. Long-term over -dose HGH administration can lead to acromegaly.
9. Injection site should often variation in case lipoatrophy.
PREGNANT AND BABY-NURSING WOMEN USAGE
It is not recommended for pregnant and nursing women to accept HGH therapy.
PEDIATRIC USAGE
Response to HGH of children is similar to that of adults in pharmacology, toxicology and pharmacokinetics, HGH is safe for pediatric use.
OLD PATIENTS USAGE
Response to HGH of old patients is similar to that of adults in pharmacology, toxicology and pharmacokinetics, HGH is safe for geriatric use.
INTERACTION WITH OTHER DRUGS
Responses to HGH therapy might be inhibited by glucocorticoid, so that hydrocortisone dosage would be lower than 10~15mg/m2 of body surface during HGH therapy.
Simultaneous using of non-androgenic steroid during HGH therapy can accelerate growth rate.
OVERDOSAGE
There is yet no report about over dosage of HGH; however, over dosage may cause some side effects, such as hypoglycemia at the beginning then succeeded with hyperglycemia. Long-term over dosage using of HGH can lead to acromegaly.
VIAL SIZE
2, 4 IU/vial
STORAGE
Keep at 2~8? away from light. The reconstituted solution mixed with Sterile Water for Injection can be stored at 2~8? for 48 hours, do not be frozen.
EXPIRY
2 years
LICENCES
GYZZS19990021(4IU/vial)
GYZZS19990022(2IU/vial)
From Somatorm site:
SOMATORM INJECTION PRODUCT INSERT
PHARMACIA EL RAMOZ GENE AND CELL PRODUCTS
SOMATORM INJECTION- Recombinant Human Growth Hormone for InjectionK
(Somatropin/rHGH, rDNA Origin)
BRIEF INTRODUCTION
is a kind of sterile, lyophilized formulation of Recombinant Human Growth Hormone (rHGH) derived from engineering E.coli, and it is identical to the natural growth hormone in amino acid sequence and three-dimension structure. is indicated for growth failure due to endogenous growth hormone deficiency (GHD) and Turner disease or Kidney failure. can be used to heal up the surgery wound or burned wound and it has good effect to preservation for human aging. Our manufacturing plants of are certified for GMP Standard by SDA.
SPECIFICATION AND INSTRUCTION
PRODUCT NAME: SOMATORM injection
Composition in effect: Recombinant Human Growth Hormone
DESCRIPTION
White loose lyophilized powder.
PHARMACOLOGY AND TOXICOLOGY
rHGH exerts the same actions of endogenous human growth hormone. It can stimulate proliferation and differentiation of epiphysis chondrocyte, stimulate growth of cartilage matrix cells, stimulate proliferation and differentiation of osteoblast; thus accelerate the liner growth rate and improve epiphysis width. Ansomone? can promote protein synthesis in whole body; reverse the negative nitrogen equilibrium caused by wound and surgery; correct the hypoproteinemia due to severe infection or hepatocirrhosis; stimulate synthesis of immune globin and proliferation of lymphadenoid, macrophage and lymphocyte, thus enhance the ability of infection resistance; stimulate proliferation of collagenocyte, fibroblast and macrophage in sites of burn and surgery, thus accelerate wound healing; promote synthesis of cardiocytes, thus improve cardiac contractility and reduce cardiac oxygen consumption; regulate lipometabolism, thus depress serum cholesterol and low density lipoprotein's level; complement insufficiency or deficiency of growth hormone, regulate adult's lipometabolism, osteometabolism, heart and kidney function.
PHARMACOKINETICS
It is reported that the equal pharmacological effect could be achieved via subcutaneous (sc) or intramuscular (IM) administration. Even though sc may lead a higher concentration of GH in plasma, IM could also yield the same IGF-I level. The absorption of GH is the relatively slow, Cmax often occurs at 3-5 hours after injection. Clearance of GH is via liver and kidney, the half-life of clearance is about 2-3hours. Uncatabolized GH excreted in urea is almost immeasurable. All of the GH in circulation system exists as a complex form with GH binding proteins that make the half-life of GH prolonged.
INDICATIONS
rHGH is indicated for the growth failure of children due to endogenous growth hormone deficiency (GHD), chronic renal insufficiency (CRI) and Turner's syndrome. Ansomone? is indicated for severe burn.
USAGE
When reconstitution, water for injection should be injected along the bottle wall, then swirl the vial with a gentle rotary motion until the contents are completely dissolved, do not shake violently.
The recommended dosage of rHGH for the treatment of children growth failure is 0.1~0.15IU/kg daily subcutaneous administration for 3 months to 3 years. Therapy regimen could be modified according to experienced doctor's suggestion.
The recommended dosage of rHGH for the treatment of severe burn is 0.2~0.4IU/kg daily subcutaneous administration for 2 weeks.
ADVERSE REACTIONS
Growth hormone may cause transient hyperglycemia; it can be recovered as the administration proceeded or terminated.
Adverse reactions occurred in about 1% short stature children in clinical trial. Common adverse reactions include slight pain, tingle, turgescence around the injection site and peripheral edema, arthralgias. All of those adverse reactions often occurred at the beginning of treatment, and were temporal and tolerable.
As with most proteins some users may report minor iritation at the injection sites via subqutaneous injection methods.
CONTRAINDICATIONS
rHGH should not be used in children whose epiphysis had been closed.
rHGH should not be used in cancer patients.
rHGH should not be used in patients in acute shock stage with severe infection.
WARNINGS AND PRECAUTIONS
rhGH therapy should be conducted on exactly diagnosed GHD patients under advice of experienced doctor.
For diabetes patients, dosage of anti-glucourea drugs should be adjusted during rhGH therapy.
For patients whose GHD were caused by encephaloma or encephalic wound, the progress and the relapse possibility of potential diseases should be closely monitored.
For ACTH deficiency patients, dosage of ATCH should be adjusted because the growth improvement effect of rhGH could be inhibited by simultaneous using of ACTH.
Thyroid gland function should be tested regularly because clinical hypothyroidism may occur to some patients during rhGH therapy. For those hypothyroid, thyroid supplementation is necessary for ensuring the therapeutic effects of rhGH.
Careful consideration should be taken if claudicating occurred during rhGH therapy because the patients who suffered from endocrine system diseases (including GHD) have such a tendency that their epiphysis plates of femur are relatively easy to separate.
Growth hormone may lead to over insulin state, attention should be paid to if lower glucose intolerance appeared.
Do not take over-dose of rhGH, one time over-dose rhGH administration can lead to low blood sugar and succeeded with high blood sugar. Long-term over -dose rhGH administration can lead to acromegaly.
Injection site should often variation in case lipoatrophy.
PREGNANT AND BABY-NURSING WOMEN USAGE
It is not recommended for pregnant and nursing women to accept rhGH therapy.
PEDIATRIC USAGE
Response to rhGH of children is similar to that of adults in pharmacology, toxicology and pharmacokinetics, rhGH is safe for pediatric use.
OLD PATIENTS USAGE
Response to rhGH of old patients is similar to that of adults in pharmacology, toxicology and pharmacokinetics, rhGH is safe for geriatric use.
INTERACTION WITH OTHER DRUGS
Responses to rhGH therapy might be inhibited by glucocorticoid, so that hydrocortisone dosage would be lower than 10~15mg/m2 of body surface during rhGH therapy.
Simultaneous using of non-androgenic steroid during rhGH therapy can accelerate growth rate.
OVERDOSAGE
There is yet no report about over dosage of rhGH; however, over dosage may cause some side effects, such as hypoglycemia at the beginning then succeeded with hyperglycemia. Long-term over dosage using of rhGH can lead to acromegaly.
VIAL DOSE
10mg, 20mg, 40mg.
Kit packs-multi vials.
1mg= 3IU
UNIQUE FORMULATION
SOMATORM conatins a unique formulation of preservatives which preserves and stabilizes the rhGH both in its dry & diluted states unlike other brands.
STORAGE
Keep away from light.
SOMATORM is stable at room temp before being diluted and is not compulsory to refrigerated(recommended). Unlike other brands which dont have this stability.
Once reconstituted the solution must be refrigerated very cold at all times(do not freeze).
Once diluted with the supplied solution SOMATORM is stable up to 2>4 weeks maximum(whilst refrigerated very cold) due to its unique formulation. Unlike other brands which are only stable for a few days.
EXPIRY
2 years
PitBullFootBall
New member
And when you posted this on bolex they took it down?
its an eye opener that somethings fishy - they could have at least re-worded it
its an eye opener that somethings fishy - they could have at least re-worded it
PitBullFootBall
New member
I just visited both sites and Mixxins right on.
Now do all rHGH's have the same product inserts? If not this is some compelling evidence.
Now do all rHGH's have the same product inserts? If not this is some compelling evidence.
PitBullFootBall
New member
^bump^
I wrote to Pharmicia El Ramoz and asked this whether they were made by Ankiebio. This is their response"
"No.
Pharmacia el ramoz is in Argentina and Somatorm is made in
Australia."
Of course, all that really means is that if they are made by AB, they're not willing to admit it. I don't know why I bothered to ask.
I really wish the guys pushing this stuff on bolex weren't such scum because I'd really like to believe there's a gh source out there for those of us who aren't rich. Probably not.
"No.
Pharmacia el ramoz is in Argentina and Somatorm is made in
Australia."
Of course, all that really means is that if they are made by AB, they're not willing to admit it. I don't know why I bothered to ask.
I really wish the guys pushing this stuff on bolex weren't such scum because I'd really like to believe there's a gh source out there for those of us who aren't rich. Probably not.
Similar threads
